MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.61 -0.60%

-$0.09 today

Market cap
$175.71M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.17M

Average 0.09M

MDWD Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

MediWound Ltd.NASDAQ: MDWD

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$338K, compared with $1.08M a year earlier. Trailing-twelve-month accounts receivables was $3.64M.

Context

  • Accounts receivables amounted to 28.8% of revenue in FY2025, up 23.7 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$338K or moves back toward the trailing-twelve-month quarterly average of $909.07K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$338K-107.0% QoQ
Last fiscal yearDec 2025
$4.88M+577.6% YoY
LTMMar 2026
$3.64M+1144.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-131.4%——
1 year+577.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
4.88M USD
Year-over-year change
+577.6%
4-year CAGR
+51.4%

Accounts Receivables vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1144.1% is the highest of 6, against a peer median of -39.0%.
  • Accounts receivables amounts to 25.1% of revenue for MDWD, versus a peer median of 12.2%.
MDWD Competitors
Accounts Receivables for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDWDMediWound Ltd.LTM Mar 2026$3.64M USD+1144.1%—25.1%
IVVDInvivyd, Inc.LTM Mar 2026$3.46M USD-39.0%—6.2%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$1.5M USD-42.4%—84.7%
IVAInventiva S.A.FY2025€816.45K EUR-70.9%-40.3%18.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$405.95K USD+181.5%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$5K USD+171.4%—0.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 USD———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$0 USD———
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding MDWD) —-39.0%-40.3%12.2%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Depreciation & Amortization1.24M1.27M1.3M1.48M1.71M
Deferred Income Tax(124K)0000
Stock-Based Compensation1.67M1.95M1.94M3.14M3.11M
Change in Working Capital162K(7.24M)2.34M1.27M4.77M
Accounts Receivables929K(7.58M)4.76M(1.02M)4.88M
Inventory257K(721K)(906K)187K(1.36M)
Accounts Payables1.72M414K(594K)406K2.35M
Other Working Capital(2.75M)645K(928K)1.7M(1.1M)
Other Non-Cash Items1.69M11.74M(9.33M)10.71M(236K)
Operating Cash Flow(8.92M)(11.89M)(10.47M)(13.62M)(14.53M)
Capital Expenditures(489K)(555K)(6.46M)(6.27M)(5.51M)
Acquisitions (Net)00000
Purchases of Investments0000(14.04M)
Sales of Investments4M0000
Other Investing Activities35K74K(27.86M)(2.12M)0
Investing Cash Flow3.55M(481K)(34.32M)(8.4M)(19.54M)
Debt Repayment000(928K)0
Common Stock Issued3K38.38M24.91M22.17M31.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.05M)(2.62M)(1.99M)(1.84M)(1.43M)
Financing Cash Flow(1.05M)35.76M22.92M19.39M29.62M
Effect of Forex Changes88K(549K)(160K)(84K)95K
Net Change in Cash(6.33M)22.85M(22.03M)(2.71M)(4.36M)
Free Cash Flow(9.41M)(12.44M)(16.93M)(19.9M)(20.04M)

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.